We are a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. We use our proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development.
Our goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need. We believe that our Research & Development Engine can result in a disruptive change that will impact pharma productivity and innovation to benefit the entire healthcare ecosystem.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.
learn MoreInveniAI is pioneering Artificial Intelligence and Big Data driven analytics applications. The company currently offers two groundbreaking artificial intelligence platforms, EvolverAI and PharmGPS® that are applied in drug discovery and development. EvolverAI is used to unearth hidden relationships between diseases, molecular targets and drugs to identify novel therapeutics and re-innovate existing drugs. PharmGPS® is a SAAS platform that is used to project the future performance trajectories of drugs in development
learn MoreE.Z. BioXcel, Center of Excellence (CoE) for Research and Development is an innovation hub focused on the development of transformative patient treatments. It houses a rich and diverse cross-functional mix of highly qualified scientific, commercial and medical experts to ensure our partners are able to innovate in an evolving healthcare environment. The center encompasses 100+ years of cumulative drug discovery, development, and management experience in over 100+ indications.
We are leveraging our artificial intelligence and big data capabilites to develop a pipeline of product candidates with a high probability of success in immuno-oncology, neurosciences, and rare diseases. List of development programs of our portfolio companies.
Therapeutic Area | COMPOUND | INDICATION | IND | Phase I/II | Phase III |
---|---|---|---|---|---|
Immuno-Oncology | BXCL701 | Neuroendocrine Prostate Cancer (tNEPC) & Pancreatic Cancer |
|
||
BXCL702 | Hematological Malignancies |
|
|||
Neuroscience | BXCL501 | Geriatric Dementia & Schizophrenia/Bipolar |
|
||
BXCL502 | Neurodegeneration |
|
|||
Neuro-oncology | BXCL101 | NF2 |
|
||
Orphan & Rare Diseases | BXCL901 | Hematology/Oncology |
|
BioXcel has a special interest in the following disease categories, where we have deep in-house expertise:
BioXcel’s partnerships are focused on the discovery and ideation of innovative drug candidates with a risk mitigated profile and improved probability of clinical and commercial success. Our partnerships are focused on de-novo drug discovery, drug re-innovation, asset rescue, indication expansion, life-cycle management, and product reformulation opportunities.